New Delhi: Vaccine manufacturer Bharat Biotech has received approval to conduct Phase-III clinical trials of an intranasal booster dose on people who have received both doses of Covaxin.
The Drug Controller General of India today gave the go-ahead for the Phase-III trials. The trials will be conducted at nine locations in the country.
An intranasal vaccine as a booster will be easier to administer in mass vaccination drives.
It has also underlined how easily a nasal vaccine can be administered and the fact that it would not need trained healthcare workers.
The Hyderabad-based vaccine manufacturer had last month sought the drug regulator's approval to conduct phase-III trials of the nasal vaccine.